Advanced search

Instruments

Name		Stock exchange	Average volume	Price	Type
LEVI STRAUSS & CO.	LEVI	Nyse +9 Other	2,053,549	22.29 USD	Stock
LEVI STRAUSS & CO.	LV2B	Deutsche Boerse AG	75	21 EUR
LEVI STRAUSS & CO.	LV2B	Börse Stuttgart	-	20.48 EUR
LEVI STRAUSS & CO.	LEVI	Wiener Boerse	-	21.15 EUR
LEVI STRAUSS & CO.	0A14	London S.E.	835	16.62 EUR
LEVI STRAUSS & CO.	LEVI *	Mexican S.E.	345	328 MXN
LEVI STRAUSS & CO.	LV2B	Frankfurt	188	18.7 EUR
LEVI STRAUSS & CO.	LV2B	BOERSE MUENCHEN	163	20.57 EUR
LEVI STRAUSS & CO.	1LEVI	Borsa Italiana	-	20.5 EUR
LEVI STRAUSS & CO.	LV2B	Berne S.E.	-	- CHF
RAMI LEVI CHAIN STORES HASHIKMA MARKETING 2006 LTD	RMLI	TEL AVIV STOCK EXCHANGE +1 Other	30,655	20,900 ILa	Stock
RAMI LEVI CHAIN STORES HASHIKMA MARKETING 2006 LTD	RLEVF	OTC Markets	0	56 USD
LEVI STRA3.531	LV2C	BOERSE MUENCHEN	-	86.3 %	Bond
LEVI STRA3.375B27		Deutsche Boerse AG	-	97.96 %	Bond
LEVI STRA3.375B27		Deutsche Boerse AG	-	98.3 %	Bond
LEVI STRA3.375B27		BOERSE MUENCHEN	-	98.22 %	Bond
LEVI STRA3.531	LV2C	Börse Stuttgart	-	85.94 %	Bond
LEVI STRA3.375B27		Börse Stuttgart	-	98.37 %	Bond
LEVI STRA3.375B27		BOERSE MUENCHEN	-	98.67 %	Bond
LEVI STRA3.531	LV2C	Deutsche Boerse AG	-	86 %	Bond

See all

News (723)

Roche: positive CHMP opinion for Alecensa	26/04	CF
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer	19/04	GL
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer	19/04	BU
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS	17/04	BU
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS	17/04	GL
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study	15/04	BU
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study	15/04	GL
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension	08/04	AQ
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure	06/03	AQ
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care	05/03	GL
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies	26/02	BU
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies	26/02	GL
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies	19/02	AQ
Roche: FDA approves allergy treatment	16/02	CF
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies	16/02	GL
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies	16/02	BU
New long-term data for Roche's Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)	01/02	AQ
New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)	01/02	BU
New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)	01/02	GL
Roche cancer immunotherapy receives new EU approval	17/01	AQ
European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types	16/01	GL
FDA grants priority review to omalizumab for food allergies	21/12	AQ
Roche - FDA grants priority review to Xolair for children and adults with food allergies based on positive National Institutes of Health phase III study results	20/12	AQ
Roche's Xolair Granted FDA Priority Review	19/12	DJ
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results	19/12	GL
FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results	19/12	BU
New data for Roche s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma	12/12	AQ
New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma	11/12	GL
New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma	11/12	BU
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A	09/12	AQ
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A	09/12	BU
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A	09/12	GL
Roche's Inavolisib Breast Cancer Drug Gets Positive Results	08/12	DJ
Roche: positive data for Kadcyla in breast cancer	08/12	CF
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment	08/12	GL
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation	08/12	GL
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment	08/12	BU
Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation	08/12	BU
Roche to advance novel obesity and diabetes treatments	05/12	AQ
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation	05/12	GL
Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation	05/12	BU
Roche to Buy Carmot Therapeutics for Up to $3.1 Billion in Bet on Obesity Treatments -- Update	04/12	DJ
Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes	04/12	GL
CHMP recommends new immunotherapy delivery method	15/11	AQ
Roche’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types	14/11	GL

1234NextSee all

Companies (18)

SHANGHAI PUDONG DEVELOPMENT BANK CO., LTD. 31 980 M $

Shanghai Pudong Development Bank Co., Ltd. is a commercial bank. The group specializes in commercial loans and public deposits levying. At the end of 2020, Shanghai Pudong Development Bank manages CNY 4,122.4 billion of current deposits and CNY 4,430.2 b ...

LEVI STRAUSS & CO. 9 143 M $

Levi Strauss & Co. is an apparel company. The Company designs and markets jeans, casual wear and related accessories for men, women and children under the Levi's, Signatureby Levi Strauss & Co., Denizen, Dockers and Beyond Yoga brands. The Company operate ...

SOCIETE INDUSTRIELLE DES TEXTILES S.A. 3 M $

Sitex SA is Tunisia-based company. The Company is primarily engaged in the production of Denim (Jeans) and Sports Wear fabrics. It is an integrated company which consists of two factories, the first is a spinning unit in Sousse, the second is a dyeing, we ...

RAMI LEVI CHAIN STORES HASHIKMA MARKETING 2006 LTD 779 M $

Rami Levi Chain Stores Hashikma Marketing 2006 Ltd. is an Israel-based discount chain store which operates 14 branches in Jerusalem as well as in the surrounding areas of Shilat (Modiin), Mishor Adomim, Mevaseret Zion and Shaar Benyamin. The Company opera ...

GENESCO INC. 306 M $

Genesco Inc. is a retailer and wholesaler of branded footwear, apparel and accessories. The Companyâs segments include Journeys Group, Schuh Group, Johnston & Murphy Group and Genesco Brands Group. The Journeys Group segment comprises the Journeys, Jour ...

SUN HING VISION GROUP HOLDINGS LIMITED 23 M $

Sun Hing Vision Group Holdings Limited is a Hong Kong-based investment holding company principally engaged in glasses-related businesses. The main businesses of the Company include the design, manufacture and sales of glasses and other related eyewear pro ...

CRYSTAL INTERNATIONAL GROUP LIMITED 1 614 M $

Crystal International Group Limited is a company principally engaged in the manufacture and distribution of clothes. The Companyâs Products are divided into five categories, namely casual wear, personal underwear, sweaters and sportswear and outdoor clo ...

HYBRID FINANCIAL SERVICES LIMITED 3 M $

Hybrid Financial Services Limited is an India-based company. The Company is engaged in the business activities of management consulting, which consists of debt recovery advise, consultancy in financial, secretarial, commercial, legal, direct and indirect ...

CREDO BRANDS MARKETING LIMITED 132 M $

Credo Brands Marketing Ltd is an India-based company, which is engaged in in the business of selling of fashion casual garments and accessories under the brand name MUFTI. The Company operates in the menâs casual wear and apparels business segment. Its ...

PT MEGA PERINTIS TBK 59 M $

PT Mega Perintis Tbk is an Indonesia-based apparel company. The Company is engaged in retail trading of apparels with a focus on menâs fashion. The Company operates under various brands, namely MANZONE that offers menâs apparel; MOC offers contemporar ...

12Next

Insiders

Levi Garraway

Levi A.
Garraway is the founder of Foundation Medicine, Inc. (founded in 2009) and Tango Therapeutics Sub, Inc. (founded in 2017).
He is currently the Director, Chief Medical Officer & Executive VP at Genentech, Inc. since 2019 and the Chief Medical Officer & Head-Product Development at Roche Holding AG.
Dr. Garraway's former positions include being the Director at the American Association for Cancer Research, Senior VP-Global Development & Medical Affairs at Eli Lilly & Co. from 2017 to 2019, and Assistant Professor at Dana-Farber Cancer Institute, Inc. from 2007 to 2011.

Richard Garraway

Richard Garraway is currently a Director at PBB Devices Ltd.
and a Director & Director-Intellectual Property at Ascension Healthcare Plc.
He was previously a Director at Novacta Biosystems Ltd., an Investment Banker at J.P.
Morgan & Co. Ltd., a Principal at Celtic Pharma Development UK Plc, and the Head-Business Development at Bedford Royalties Ltd.
Garraway holds an MBA and a doctorate from London Business School.

Garraway G. Kendall

Alvin R. Garraway

Alvin R.
Garraway is a Director of Valley Bancorp (Nevada) and a Member of the Nevada Society of CPAs and The American Institute of Certified Public Accountants.
Prior to joining Valley Bancorp (Nevada) in April 19, 2006, he was President and Controller of Oasis Residential, Inc. and an Audit Partner of Horwath Velez & Co. PSC.
He is a Certified Public Accountant.

Kendall Garraway

Kendall Garraway currently works at Cotton, Inc., as Director.

Nick Garraway

Kate Garraway

David A. Garraway

David A.
Garraway currently works as a Director at Vroom Automotive Finance Corp.

Elma Garraway

Elma Garraway currently works at Doctors Hospital Health System Ltd., as Director.

Aimee Garraway

Aimee Garraway worked as an Operations Manager at John Charcol Middle East Ltd.

No results for this search